EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 43 / No 1 (March 2011) J Extra Corpor Technol, 43 1 (2011) 5-12 References
Free Access
Review
Issue
J Extra Corpor Technol
Volume 43, Number 1, March 2011
Page(s) 5 - 12
DOI https://doi.org/10.1051/ject/201143005
Published online 15 March 2011
  1. Warkentin TE. Heparin-induced thrombocytopenia: Pathogenesis and management. Br J Haematol. 2003;12:535–55. [CrossRef] [Google Scholar]
  2. Schmugge M, Risch L, Huber AR, Benn A, Fischer JE. Heparin-induced thrombocytopenia-associated thrombosis in pediatric intensive care patients. Pediatrics. 2002;109:e10. [CrossRef] [PubMed] [Google Scholar]
  3. Boshkov LK, Ibsen L, Kirby A, Ungerleider R, Shen I. Heparin-induced thrombocytopenia (HIT) in neonates and very young children undergoing congenital cardiac surgery:A likely under-recognized complication with significant morbidity and mortality: Report of 4 sequential cases. J Thromb Haemost. 2003;1(Suppl 1):1494a. [Google Scholar]
  4. Etches WS, Stang LJ, Conradi AG. Incidence of heparin-induced thrombocytopenia in a pediatric intensive care population. Blood. 2003;102(Suppl.):536a. [Google Scholar]
  5. Klenner AF, Lubenow N, Raschke R, Greinacher A. Heparin-induced thrombocytopenia in children: 12 new cases and review of the literature. Thromb Haemost. 2004;91:791–824. [Google Scholar]
  6. Risch L, Fischer JE, Herklotz R, Huber AR. Heparin-induced thrombocytopenia in pediatrics: Clinical characteristics, therapy, outcomes. Intensive Care Med. 2004;30:1615–24. [CrossRef] [PubMed] [Google Scholar]
  7. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg. 2003;76:638–48. [CrossRef] [Google Scholar]
  8. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: Towards consensus. Thromb Haemost. 1998;79:1–7. [CrossRef] [PubMed] [Google Scholar]
  9. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502–7. [CrossRef] [Google Scholar]
  10. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia, 3rd Ed. New York: Marcel Dekker Inc.; 2004:53–106. [Google Scholar]
  11. Levy JH, Tanaka KA, Hursting MJ. Reducing thrombotic complications in the perioperative setting: An update on heparin induced thrombocytopenia. Anesth Analg. 2007;105:570–82. [CrossRef] [PubMed] [Google Scholar]
  12. Bennett-Guerrero E, Slaughter TF, White WD, et al. Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery. J Thorac Cardiovasc Surg. 2005;130:1567–72. [CrossRef] [Google Scholar]
  13. Mullen MP, Wessel DL, Thomas KC, et al. The incidence and implications of anti-heparin-platelet factor 4 antibody formation in a pediatric cardiac surgical population. Anesth Analg. 2008;107:371–8. [CrossRef] [PubMed] [Google Scholar]
  14. Greinacher A, Levy JH. HIT happens: Diagnosing and evaluating the patient with heparin-induced thrombocytopenia. Anesth Analg. 2008;107:356–8. [CrossRef] [PubMed] [Google Scholar]
  15. Severin T, Zieger B, Sutor AH. Anticoagulation with recombinant hirudin and danaparoid sodium in pediatric patients. Semin Thromb Hemost. 2002;28:447–54. [Google Scholar]
  16. Kelton JG. The pathophysiology of heparin-induced thrombocytopenia: Biological basis for treatment. Chest. 2005;127(Suppl):9s–20s. [Google Scholar]
  17. Warkentin T. New approaches to the diagnosis of heparin induced thrombocytopenia. Chest. 2005;127(Suppl):35s–45s. [Google Scholar]
  18. Basci S, DePalma R, Visentin GP, Gorski J, Aster RH. Complexes of heparin and platelet factor 4 specifically stimulate T cells from patients with heparin-induced thrombocytopenia and thrombosis. Blood. 1999;94:208–15. [CrossRef] [PubMed] [Google Scholar]
  19. Risch L, Huber AR, Schmugge M. Diagnosis and treatment of heparin-induced thrombocytopenia in neonates and children. Thromb Res. 2006;118:123–35. [CrossRef] [Google Scholar]
  20. Levy JH, Winkler AM. Heparin-induced thrombocytopenia and cardiac surgery. Curr Opin Anaesthesiol. 2010;23:74–9. [CrossRef] [PubMed] [Google Scholar]
  21. Greinacher A. Heparin-induced thrombocytopenia. J Thromb Haemost. 2009;7(Suppl 1):9–12. [CrossRef] [Google Scholar]
  22. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: A meta-analysis. Blood. 2005;106:2710–5. [CrossRef] [PubMed] [Google Scholar]
  23. Severin T, Sutor AH. Heparin-induced thrombocytopenia in pediatrics. Semin Thromb Hemost. 2001;27:293–9. [Google Scholar]
  24. Menajovsky LB. Heparin-induced thrombocytopenia: Clinical manifestations and management strategies. Am J Med. 2005;118(Suppl 8A):21–30. [CrossRef] [Google Scholar]
  25. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: Recognition, treatment and prevention. Chest. 2004;126:311s–37s. [Google Scholar]
  26. Jy W, Mao WW, Horstman LL, Valant PA, Ahn YS. A flow cytometric assay of platelet activation marker P-selectin (CD62P) distinguishes heparin-induced thrombocytopenia (HIT) from HIT with thrombosis (HITT). Thromb Haemost. 1999;82:1255–9. [CrossRef] [PubMed] [Google Scholar]
  27. Lo GK, Warkentin TE. Preliminary evaluation of a clinical scoring system for estimating the pretest probability of heparin-induced thrombocytopenia: The “4 T’s”. Blood. 2003;102:536a. [Google Scholar]
  28. Ortel T. Heparin-induced thrombocytopenia: When a low platelet count is mandate for anticoagulation. Hematology (Am Soc Hematol Educ Program). 2009:225–32. [CrossRef] [Google Scholar]
  29. Deitcher S, Topoulos AP, Bartholomew JR, Kichuk-Chrisant M. Lepirudin anticoagulation for heparin-induced thrombocytopenia. J Pediatr. 2002;140:264–6. [CrossRef] [Google Scholar]
  30. Lubenow N, Greinacher A. Drugs for the prevention and treatment of thrombosis in patients with heparin induced thrombocytopenia. Am J Cardiovasc Drugs. 2001;1:429–43. [CrossRef] [PubMed] [Google Scholar]
  31. Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. N Engl J Med. 2006;355:809–17. [CrossRef] [PubMed] [Google Scholar]
  32. Greinacher A, Warkentin TE. Treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia, 3rd Ed. New York: Marcel Dekker Inc; 2004:335–70. [Google Scholar]
  33. Gates R, Yost P, Parker B. The use of bivalirudin for cardiopulmonary bypass anticoagulation in pediatric heparin-induced thrombocytopenia patients. Artif Organs. 2010;34:667–9. [PubMed] [Google Scholar]
  34. Potter KE, Raj A, Sullivan JE. Argatroban for anticoagulation in pediatric patients with heparin-induced thrombocytopenia requiring extracorporeal life support. J Pediatr Hematol Oncol. 2007;29:265–8. [CrossRef] [PubMed] [Google Scholar]
  35. Alsoufi B, Boshkov LK, Kirby A, et al. Heparin-induced thrombocytopenia (HIT) in pediatric cardiac surgery: An emerging cause of morbidity and mortality. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2004;7:155–7. [CrossRef] [Google Scholar]
  36. Kawada T, Kitagawa H, Hoson M, Okada Y, Shiomura J. Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation. Hematol Oncol Clin North Am. 2000;14:445–57. [CrossRef] [Google Scholar]
  37. Dager WE, Gosselin RC, Yoshikawa R, Owings JT. Lepirudin in heparin-induced thrombocytopenia and extracorporeal membranous oxygenation. Ann Pharmacother. 2004;38:598–601. [CrossRef] [PubMed] [Google Scholar]
  38. Knoderer CA, Knoderer HM, Turrentine MW, Kumar M. Lepirudin anticoagulation for heparin-induced thrombocytopenia after cardiac surgery in a pediatric patient. Pharmacotherapy. 2006;26:709–12. [CrossRef] [PubMed] [Google Scholar]
  39. Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost. 2008;99:830–9. [Google Scholar]
  40. Selleng K, Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med. 2007;35:1165–76. [CrossRef] [PubMed] [Google Scholar]
  41. Casserly IP, Kereiakes DJ, Gray WA, et al. Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration. Thromb Res. 2004;113:115–21. [CrossRef] [Google Scholar]
  42. Jabr K, Johnson JH, McDonald MH, et al. Plasma-modified ACT can be used to monitor bivalirudin (angiomax) anticoagulation for on-pump cardiopulmonary bypass surgery in a patient with heparin-induced thrombocytopenia. J Extra Corpor Technol. 2004;36:174–7. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  43. Dyke CM, Koster A, Veale JJ, Maier GW, McNiff T, Levy JH. Preemptive use of bivalirudin for urgent on-pump coronary artery bypass grafting in patients with potential heparin-induced thrombocytopenia. Ann Thorac Surg. 2005;80:299–303. [CrossRef] [Google Scholar]
  44. Dyke CM, Smedira NG, Koster A, et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: The EVOLUTION-ON study. J Thorac Cardiovasc Surg. 2006;131:533–9. [CrossRef] [Google Scholar]
  45. Smedira NG, Dyke CM, Koster A, et al. Anticoagulation with bivalirudin for offpump coronary artery bypass grafting: The results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg. 2006;131:686–92. [CrossRef] [Google Scholar]
  46. Young G. New anticoagulants in children. Hematology (Am Soc Hematol Educ Program). 2008:245–50. [CrossRef] [Google Scholar]
  47. Young G, Tarantino MD, Wohrly J, Weber LC, Belvedere M, Nugent DJ. Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosis. J Thromb Haemost. 2007;5:1654–9. [CrossRef] [Google Scholar]
  48. Koster A, Weng Y, Bottcher W, Gromann T, Kuppe H, Hetzer R. Successful use of bivalirudin in a patient with acute HIT. Ann Thorac Surg. 2007;83:1865–7. [CrossRef] [Google Scholar]
  49. Mejak B, Giacomuzzi C, Heller E, et al. Argatroban usage for anticoagulation for ECMO on a post-cardiac patient with heparin-induced thrombocytopenia. J Extra Corpor Technol. 2004;36:178–81. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  50. Scott LK, Grier LR, Conrad SA. Heparin-induced thrombocytopenia in a patient receiving extracorporeal membrane oxygenation with argatroban. Pediatr Crit Care Med. 2006;7:473–5. [CrossRef] [PubMed] [Google Scholar]
  51. Tcheng WY, Wong WY. Successful use of argatroban in pediatric patients requiring anticoagulant alternatives to heparin. Blood (ASH Annual Meeting Abstracts). 2004;104:4085. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.